Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 13/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.32 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286377 | 0.83 | GABRA5 (0.39) | GABRA5L3MBTL1ALDH1A1 | |
| SCHEMBL535992 | 0.82 | GABRA5 (0.55) | GABRA5 | |
| SCHEMBL2101397 | 0.81 | GABRA5 (0.51) | GABRA5 | |
| SCHEMBL286102 | 0.80 | KDM5A (0.32) | GABRA5CA12CA1CA2CA9 | |
| SCHEMBL286035 | 0.80 | GABRA5 (0.34) | GABRA5CA12CA1CA2CA9 | |
| SCHEMBL286369 | 0.76 | NR1H4 (0.40) | GABRA5NR1H4L3MBTL1 | |
| SCHEMBL285772 | 0.74 | GABRA5 (0.42) | GABRA5 | |
| SCHEMBL286709 | 0.74 | KMT2A (0.40) | GABRA5L3MBTL1ALDH1A1 | |
| SCHEMBL286289 | 0.73 | GABRA5 (0.65) | GABRA5 | |
| SCHEMBL286143 | 0.73 | ALDH1A1 (0.35) | GABRA5NR1H4L3MBTL1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163728-B2 | Pyrazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2427455-A1 | ISOXAZOLE-PYRAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20100286115-A1 | PYRAZOLES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| WO-2010127975-A1 | ISOXAZOLE-PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286115-A1 | PYRAZOLES | GABRA5, GABRA1, GABRA3 | GABRA5 1/4885CA12 4587/4885CA1 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.